CHRN earnings analysis
What we found in CHRN's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Ekso Bionics Holdings, Inc. provides cutting-edge exoskeleton and complementary products for healthcare and personal use, targeting individuals with physical disabilities. The company reported a significant revenue decrease of 29% for 2025, attributed primarily to decreased sales in the Enterprise Health market, while initiating new sales avenues in Personal Health following Medicare reimbursements for the Ekso Indego Personal device. Financial constraints and upcoming business combinations signal challenges ahead.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Product Roadmap Expansion
- Plans to market the MediTouch BalanceTutor starting early 2026, expected to complement existing exoskeleton products.
- Medicare Approval Boosts Sales Potential
- Medicare approved the Ekso Indego Personal for $91,000 reimbursement, potentially increasing demand among estimated 309,000 SCI patients in the U.S.
- Increased Focus on Personal Health Market
- Witnessed increased claims and reimbursements in the Personal Health market, expected greater year-over-year contribution in 2026.
- Partnerships with Leading DMEs Established
- Signed agreements with National Seating & Mobility, Bionic Prosthetics & Orthotics Group, and Ottobock to enhance go-to-market strategies.
- Reduction in Operating Expenses
- Operating expenses were stable despite a drop in revenue, indicating cost control efforts.
- Successful Completion of Preferred Stock Placement
- Completed a Private Placement generating approximately $5.3 million for working capital needs.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Decline Threats
- Revenue fell by $5.1 million (29%) from 2024 to 2025 primarily due to decreased Enterprise Health device sales.
- Financial Stability Concerns
- As of December 31, 2025, the company had a cash balance of only $1.2 million and substantial operational losses, raising doubts about liquidity.
- Rising Competition Impact
- Increasing competition in healthcare technology, especially due to price-based pressures, negatively impacting sales, particularly in EMEA.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-4.91
- Gross margin
- 53%
- Segment
- Enterprise Health
- Segment
- Personal Health
What they said about what is next.
Revenue is expected to primarily derive from Enterprise Health but with Personal Health sales gradually contributing more. Detailed annual guidance to be discussed in earnings call.
The filing reads worse than the one before it.
What came before.
- 10-Q · October 28, 2025
- Ekso Bionics Holdings, Inc. reported a slight increase in revenue of 2% to $4.227 million for Q3 2025 compared to Q3 2024. The company achieved a significant reduction in net loss, down 31% year-over-year, while gross…
- 10-Q · July 28, 2025
- Ekso Bionics Holdings, Inc. reported a significant decline in revenue of 58% to $2.06 million for Q2 2025 compared to Q2 2024, largely due to delays in Enterprise Health device sales transitioning to Personal Health…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CHRN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever